Suggested remit: To appraise the clinical and cost effectiveness of filgotinib within its marketing authorisation for treating axial spondyloarthritis.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- Cost Comparison Standard
- ID number:
- 6594
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
- External Assessment Group:
- Kleijnen Systematic Reviews Ltd
Stakeholders
- Companies sponsors
- Alfasigma UK Ltd
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Action on Pain
- Arthritis Action
- Arthritis and Musculoskeletal Alliance
- Brain and Spine Foundation
- National Axial Spondyloarthritis Society
- Pain Concern
- Pain UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- STEPS
- Versus Arthritis
- Professional groups
- British Geriatrics Society
- British Institute of Musculoskeletal Adolescent Rheumatology
- British Myology Society
- British Orthopaedic Association
- British Pain Society
- British Society for Paediatric and
- British Society for Rheumatology
- British Society of Rehabilitation
- Chartered Society of Physiotherapy
- Musculoskeletal Medicine Society
- Physiotherapy Pain Association
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Occupational Therapists
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Endocrinology
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- ADVANZ Pharma (golimumab)
- AbbVie (adalimumab, upadacitinib)
- Amgen (adalimumab)
- Biogen Biosimilars (adalimumab, etanercept, infliximab)
- Celltrion Healthcare (adalimumab, infliximab)
- Eli Lilly (ixekizumab)
- Fresenius Kabi (adalimumab)
- Janssen-Cilag (infliximab, golimumab)
- Novartis (secukinumab)
- Pfizer (etanercept, infliximab, tofacitinib)
- Sandoz (adalimumab, etanercept, infliximab)
- UCB Pharma (bimekizumab, certolizumab pegol)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Government
- Welsh Health Specialised Services Committee
- Relevant research groups
- Bone Research Society
- Chronic Pain Policy Coalition
- Cochrane Musculoskeletal Group
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
- Orthopaedic Research UK
- Pain Relief Foundation
- Society for Back Pain Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 March 2026 | Invitation to participate |
| 15 December 2025 - 21 January 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6594 |
| 15 December 2025 | In progress. Scoping commencing |
| 02 October 2025 | Note - Note added to the project documents |
| 15 May 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual